Current Trials

Halifax Health – Center for Oncology

Clinical Trials Available for Recruitment
For further information contact the Clinical Trials Department at 386.425.4213

Breast – Agendia FLEX Registry- Breast Cancer

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)

  • Adult males and female patients with: Stage I, II or III who receive MammaPrint, with or without BluePrint testing.
  • New Primary Lesion
  • Excluded if: Metastatic Disease, Recurrent Disease, Stage 0 Disease

Consent available at site

Myelodysplastic Syndromes & Acute Myeloid Leukemia – Protocol ID: Connect® MDS and AML AZA-MDS-006

The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

  • Newly diagnosed, Myleofibrosis Disease, primary or secondary MDS or AML or Idiopathic Cytopenia of Undetermined Significance (ICUS)
  • The Myelofibrosis cohort includes 2 sub-cohorts:
    • 1. Patients receiving 1st active treatment for MR (N=400).
    • 2. Patients receiving 1st treatment MF related cytopenias (N=400)
  • The MF cohort allows enrollment with DX of MDS/MPN, excluding JMML
  • MDS / ICUS patients must be at least 18 years old
  • AML patients must be at least 55 years old
  • No active treatment (disease modifying) agents for ICUS or MDS prior to enrollment
  • AML patients may have begun active, disease modifying treatment within 14 days of informed consent date
  • Supportive care growth factors, transfusions, etc. are allowed prior to enrollment
  • Confirmed diagnosis made up to 60 days prior to the date of informed consent.
  • All supporting diagnostic reports go through central eligibility review.

Consent available at site


Connected articles